Fucoidan for Managing and Treating Dementia
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder, and the most common cause of dementia. It occurs as a result of build-up of abnormal proteins and is characterized by two neuropathological hallmarks, amyloid beta deposition, and aggregation of phosphorylated tau. The major causes of AD are not fully known; however, it believed to be caused by some factors, including, but not limited to, genetic, environmental, and lifestyle modifications. AD is a progressive type of disease that makes individuals living with it to live a dependent life, which could be frustrating to both the patients and caregivers. Recently, there's no available cure for AD, although, there are some medications used for its management, however, with some adverse side effects. Therefore, the quest for AD drug discovery development has been ongoing for decades. Natural products have been recommended to be employed in experimental research to combat AD through the use of transgenic mice or induction of AD-like symptoms because they present with minimal side effects. Fucoidan is the general name for sulfated glycans obtained from brown seaweeds. They possess antioxidant, anti-inflammatory, anticholinergic, together with cognitive enhancing functions. Above all, they are responsible for the production of favorable gut microbiota via an increase in short-chain fatty acids production. Hence, they have been recommended to have the potential of relieving AD-like symptoms and been incorporated into AD drug discovery research. This chapter explores some mechanistic actions of fucoidan in carrying out its antidementia properties in AD research both in vivo and in vitro .
Fields of Study & Subjects
Seaweed-derived Bioactive Compounds
Alzheimer's disease research and treatments
Medicinal Plants and Neuroprotection
Publication details
- Journal / source
- CRC Press eBooks
- Pages
- 137–142
- Publication date
- 31 March 2026
- Language
- EN
- Document type
- Book chapter